Promedior, Inc. presented at the American Society of Hematology (ASH) meeting positive results from Stage 1 of its adaptive two-stage Phase 2 trial investigating PRM-151 use in patients with myelofibrosis. The treatment, a novel anti-fibrotic immunotherapeutic, yielded an overall response rate of 43% after 6 months of administration, which greatly surpassed the pre-specified efficacy criteria needed to begin Stage 2.
“These promising clinical data in myelofibrosis in patients highlight the differentiated benefits of PRM-151, showing an unprecedented rate of reversing bone marrow fibrosis,” said Suzanne L. Bruhn, PhD, President and Chief Executive Officer of Promedior, in a company news release. “Further, by validating PRM-151’s novel mechanism of action to reverse fibrosis, this study demonstrates the broad potential in a range of other fibrotic diseases.”
Other results identified a reduction of bone marrow fibrosis by at least one grade in 42% of treated patients, correlating to improvements in anemia and thrombocytopenia. “We are encouraged by the favorable safety profile and clinical activity of PRM-151 demonstrated in the first stage of this trial, and are excited to see that a reduction of bone marrow fibrosis by PRM-151 is associated with signs of improved hematopoiesis,” said Srdan Verstovsek, MD, PhD, principal investigator and ASH presenter. “There is tremendous enthusiasm for PRM-151 among investigators and patients, and we look forward to moving forward with Stage 2 of this important clinical trial.”
Eleven of 25 patients able to be evaluated in Stage 1 already showed other improvements that included 4 IWG-MRT Clinical Improvement Symptom responses and reduced splenomegaly. Twenty-seven patients with primary myelofibrosis, post-polycythemia vera MF, or post-essential thrombocythemia have already enrolled in the trial, and more are being sought for Stage 2 of the trial.
So what’s next in line for Promedior? “We will continue to move PRM-151 forward as a new treatment option for patients with myelofibrosis and other fibrotic diseases,” said Dr. Bruhn. “We expect to initiate the next stage of PRM-151’s Phase 2 clinical program in myelofibrosis in the first half of 2015.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?